Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2014-01-02
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-03 (study day 2.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-03 (study day 2.0); relationship: PROBABLE
mild
assessed
Mild DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2014-01-09 (study day 8.0); relationship: REMOTE
Data queries
No data queries.